TARS
Tarsus Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▼ Seven executives at Tarsus Pharmaceuticals, including the CEO, COO,…
- Jun 15 to Jun 17 ▼ 3 days of insider sells: $2.5M by 4 insiders, avg $61.55
- Aug 6 Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and rais…
- Aug 6 Offering: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Mil…
- Aug 6 Tarsus Pharmaceuticals announced an oversubscribed $125.0 million PI…
- Aug 6 ▲ Tarsus Pharmaceuticals announced a definitive agreement to acquire A…
- Aug 6 Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to…
- Aug 26 HSR Early Termination: Tarsus Pharmaceuticals, Inc…
- Sep 1 to Sep 4 ▼ 3 days of insider sells: $4.2M by 3 insiders, avg $84.10
- Sep 15 ▼ 1 insider sell $979.7K at $78.38
- Sep 30 ▲ 4 funds open new positions (13F)
- Nov 3 ▲ Earnings: TARS Q3 2026 Earnings: EPS $-0.78 (+72.0% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $7.6M.
- InstitutionsBULLISH
Q3 2026: 30 added (4 new), 19 trimmed or exited. Largest new: Aberdeen Group $39.7M, Marshall Wace $11.7M.
- AnalystsBULLISH
15 of 16 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.044 → −$0.275 over 90 days.
- Short sellersSTEADY
Short interest +5.8% to 6.07M shares. 6.9 days to cover, ≈12.3% of shares.
- TrendUPTREND
5% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $250.4M |
| Assenagon Asset Management S.A. | TRIM | $48.4M |
| Aberdeen Group plc | NEW | $39.7M |
| UBS Group AG | DOUBLED | $37.1M |
| WASATCH ADVISORS LP | ADD | $36.8M |
| Qube Research & Technologies Ltd | DOUBLED | $28.0M |
| BARCLAYS PLC | DOUBLED | $20.6M |
| MARSHALL WACE, LLP | NEW | $11.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
16 analystsPrice is below the lowest target. Median implies +32%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 4, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 8, 2026 | Jefferies MAINTAIN | Buy |
| Aug 12, 2026 | Oppenheimer MAINTAIN | Outperform |
| Jul 31, 2026 | Mizuho MAINTAIN | Outperform |
| Jul 21, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Clase Neera Chief Commercial Officer Nov 3, 2026 | AWARD | 10,587 sh |
Clase Neera Chief Commercial Officer Nov 3, 2026 | AWARD | 6,678 sh |
PYOTT DAVID E I Director Sep 15, 2026 | EXERCISE | 201 sh |
YARNO WENDY L Director Sep 15, 2026 | EXERCISE | 302 sh |
LINK WILLIAM J PHD Director Sep 15, 2026 | SELL | $914.5K |
LINK WILLIAM J PHD Director Sep 15, 2026 | SELL | $5.3K |
LINK WILLIAM J PHD Director Sep 15, 2026 | EXERCISE | 201 sh |
LINK WILLIAM J PHD Director Sep 15, 2026 | SELL | $60.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.28 | -$0.59–$0.14 | +91.9% | $211.0M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 1 press release · 2 bullish · 3 bearish · 2 mixed · 13 neutral- NEUTRAL 144Nov 13, 2026
CEO Bobak Azamian filed a Form 144 notice of intent to sell 10,000 shares of Tarsus…
The 144 filing signals intent to sell but the amount is small and routine for a CEO. Monitor whether the sale actually executes on Form 4; if it does, watch for any pattern of larger sales in…
- NEUTRAL 3Nov 5, 2026
Neera Clase, the new Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 3 initial…
Monitor for future Form 4 filings by the new CCO for any open-market purchases or sales, which could signal insider conviction. No immediate trading catalyst.
- NEUTRAL SC 13GNov 5, 2026
FMR LLC (Fidelity) filed a Schedule 13G disclosing a 6.4% passive stake in Tarsus Pharmaceuticals…
Fidelity's new 6.4% passive stake signals institutional confidence in Tarsus' commercial trajectory following strong XDEMVY sales. Monitor for any future 13G amendments showing position increases or…
- NEUTRAL 8-KNov 3, 2026
Tarsus Pharmaceuticals reported Q3 2026 XDEMVY net product sales of $194.6 million, up ~64% YoY…
The core XDEMVY franchise continues to grow at ~64% YoY with strong refill rates, but the $632M IPRD charge and cash burn from acquisitions will pressure the balance sheet. Monitor the Q3 10-Q for…
All TARS filing & press-release reports (21)
- 144 reportNov 13, 2026
- 3 reportNov 5, 2026
- SC 13G reportNov 5, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- INST-CLUSTER reportOct 16, 2026
- S-3ASR reportOct 13, 2026
- S-3ASR reportOct 13, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 3, 2026
- 144 reportSep 2, 2026
- 144 reportSep 1, 2026
- 144 reportAug 19, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportAug 5, 2026
- 144 reportJun 16, 2026
- 144 reportJun 15, 2026
- CLUSTER reportMar 16, 2026